- €31.11m
- €24.99m
- €13.08m
- 87
- 29
- 82
- 77
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.77 | ||
| PEG Ratio (f) | 3.86 | ||
| EPS Growth (f) | 4.26% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.3 | ||
| Price to Tang. Book | 3.37 | ||
| Price to Free Cashflow | 47.56 | ||
| Price to Sales | 2.38 | ||
| EV to EBITDA | 11.42 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 18.51% | ||
| Return on Equity | 21.93% | ||
| Operating Margin | 13.96% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 10.05 | 7.12 | 9.36 | 10.95 | 13.08 | 15 | 17 | 5.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +206.28 | +6.24 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biohit Oyj is a Finland-based company engaged in the development, manufacture and marketing of diagnostic tests and analysis systems. The Company operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. It provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Company’s products are used in hospitals, healthcare centers and research institutions. It operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.
Directors
- Osmo Suovaniemi CHM (78)
- Paivi Siltala CEO
- Jussi Hahtela CFO
- Franco Aiolfi CEX (70)
- Graham Johnson CEX
- Minna Maki VRD (49)
- Ilari Patrakka DSL
- Annika Astola MGB (43)
- Suvi Elomaa MGB
- Daniela Soderstrom MGB (30)
- Liu Feng DRC
- Matti Harkonen DRC
- Lea Paloheimo DRC (68)
- Eero Lehti IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 9th, 1988
- Public Since
- June 18th, 1999
- No. of Employees
- 42
- Sector
- Office Equipment
- Industry
- Technology
- Exchange
OMX Nordic Exchange - Helsinki- Shares in Issue
- 15,173,593
- Address
- Laippatie 1, HELSINKI, 00880
- Web
- https://www.biohithealthcare.com/
- Phone
- +358 9773861
- Auditors
- PricewaterhouseCoopers Oy
Upcoming Events for BIOBV
FAQ
What is the Biohit Oyj share price?
As of Today at 19:04 UTC, shares in Biohit Oyj are trading at €2.05. This share price information is delayed by 15 minutes.
How has the Biohit Oyj share price performed this year?
Shares in Biohit Oyj last closed at €2.05 and the price had moved by +16.48% over the past 365 days. In terms of relative price strength the Biohit Oyj share price has outperformed the FTSE Global All Cap Index by +9.35% over the past year.
What are the analyst and broker recommendations for Biohit Oyj?
The overall consensus recommendation for Biohit Oyj is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Biohit Oyj dividend yield?
Biohit Oyj does not currently pay a dividend.
Does Biohit Oyj pay a dividend?
Biohit Oyj does not currently pay a dividend.
When does Biohit Oyj next pay dividends?
Biohit Oyj does not currently pay a dividend.
How do I buy Biohit Oyj shares?
To buy shares in Biohit Oyj you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biohit Oyj?
As of the previous close price of €2.05, shares in Biohit Oyj had a market capitalisation of €31.11m.
Where are Biohit Oyj shares listed?
Here are the trading details for Biohit Oyj:
- Country of listing: Finland
- Exchange: HEX
- Ticker Symbol: BIOBV
What kind of share is Biohit Oyj?
Based on an overall assessment of its quality, value and momentum Biohit Oyj is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biohit Oyj share price forecast for 2024?
The analyst consensus target price for shares in Biohit Oyj is €2.40. That is 17.07% above the last closing price of €2.05.
Analysts covering Biohit Oyj currently have a consensus Earnings Per Share (EPS) forecast of €0.13 for the next financial year.
What is the trend in the Biohit Oyj share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biohit Oyj. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -9.94%.
As of the last closing price of €2.05, shares in Biohit Oyj were trading +5.44% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biohit Oyj PE Ratio?
The Biohit Oyj PE ratio based on its reported earnings over the past 12 months is 15.77. The shares last closed at €2.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biohit Oyj?
Biohit Oyj's management team is headed by:
- Osmo Suovaniemi - CHM
- Paivi Siltala - CEO
- Jussi Hahtela - CFO
- Franco Aiolfi - CEX
- Graham Johnson - CEX
- Minna Maki - VRD
- Ilari Patrakka - DSL
- Annika Astola - MGB
- Suvi Elomaa - MGB
- Daniela Soderstrom - MGB
- Liu Feng - DRC
- Matti Harkonen - DRC
- Lea Paloheimo - DRC
- Eero Lehti - IND